Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals' stock has experienced a significant decline over the past six months. Key events impacting the stock include Q3 2025 financial results, the announcement of Bitcoin conversion, a reverse stock split, and regulatory milestones. The company reported a net loss of $2 million in Q3 2025, an improvement from a $2.8 million net loss in Q3 2024, yet the stock declined by 4.12% in premarket trading following the announcement. The announcement to convert a portion of its cash reserves into Bitcoin led to an immediate plunge in the stock price. The company undertook a 1-for-20 reverse stock split to maintain its Nasdaq listing. Positive regulatory news, such as the USPTO granting a new patent for ibezapolstat and the EMA's positive opinion on the Pediatric Investigation Plan for ibezapolstat, have been reported.

There is no explicit information indicating demand seasonality for Acurx Pharmaceuticals, Inc.'s products or services. Demand for its products, once commercialized, would likely be driven by the prevalence and incidence of the targeted infections, which typically do not exhibit strong seasonal patterns. The company's revenue is currently zero, as it is in the development stage.

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics to combat difficult-to-treat bacterial infections. The company's primary focus is on developing antibiotic candidates that target the DNA polymerase IIIC enzyme. Its lead product candidate, ibezapolstat, has completed Phase 2 clinical trials for Clostridioides difficile infection (CDI) and is currently Phase 3 ready. Acurx is also developing ACX-375C for Gram-positive bacterial infections and has preclinical programs for ABSSSI and inhalational anthrax.

Acurx Pharmaceuticals, Inc. is headquartered in Staten Island, New York, United States. The company plans to initiate international clinical trials for ibezapolstat and has received a positive opinion from the EMA regarding its Pediatric Investigation Plan, indicating a strategic focus on European markets.

Acurx Pharmaceuticals' brand reputation has been influenced by both positive scientific and regulatory advancements, alongside negative investor sentiment due to financial performance and a controversial corporate decision. Positive contributions include regulatory successes, patent grants and scientific publications, and research grants. Conversely, the company's reputation among investors has been negatively affected by stock performance, the Bitcoin investment, and continuing losses.

Acurx Pharmaceuticals, Inc. has 17 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 55,793 shares. Institutional investors own 11.53% of Acurx Pharmaceuticals' stock. Insider ownership stands at 8.46% of the shares outstanding.